Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in
older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and
investigate associated safety, tolerability, target engagement, cognition, and functional
status as initial proof-of-concept study
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio